▎Armstrong2026年2月13日,劲方医药KRAS G12D抑制剂GFH375拟纳入突破治疗药物程序,用于至少接受过一种系统性治疗并具有KRAS G12D突变的非小细胞肺癌(NSCLC)患者。GFH375为一款高选择性的强效KRAS G12D(on/off)双重作用机制的抑制剂。GFH375在KRAS G12D的竞争格局中处于领先地位。去年8月,劲方医药披露了GFH375治疗NSCLC的1...
Source Link▎Armstrong2026年2月13日,劲方医药KRAS G12D抑制剂GFH375拟纳入突破治疗药物程序,用于至少接受过一种系统性治疗并具有KRAS G12D突变的非小细胞肺癌(NSCLC)患者。GFH375为一款高选择性的强效KRAS G12D(on/off)双重作用机制的抑制剂。GFH375在KRAS G12D的竞争格局中处于领先地位。去年8月,劲方医药披露了GFH375治疗NSCLC的1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.